COMPARISON OF PROLIFERATING CELL NUCLEAR ANTIGEN VERSUS THE MORE STANDARD MEASURES OF RECTAL MUCOSAL PROLIFERATION RATES IN SUBJECTS WITH AHISTORY OF COLORECTAL-CANCER AND NORMAL AGE-MATCHED CONTROLS
J. Einspahr et al., COMPARISON OF PROLIFERATING CELL NUCLEAR ANTIGEN VERSUS THE MORE STANDARD MEASURES OF RECTAL MUCOSAL PROLIFERATION RATES IN SUBJECTS WITH AHISTORY OF COLORECTAL-CANCER AND NORMAL AGE-MATCHED CONTROLS, Cancer epidemiology, biomarkers & prevention, 4(4), 1995, pp. 359-366
Measurement of proliferation rates by the more standard in vitro uptak
e techniques of [H-3]thymidine and 5'-bromo-2'-deoxyuridine (BrdUrd) l
abeling indices (LIs) were compared to proliferating cell nuclear anti
gen (PCNA) in rectal mucosal biopsies from 16 subjects with resected c
olorectal cancer and 14 normal age-matched controls, Correlation coeff
icients for BrdUrd versus PCNA, [H-3]thymidine versus PCNA, and BrdUrd
versus [H-3]thymidine were 0.691, 0.876, and 0.770, respectively, No
significant differences (P > 0.05) were detected in total mean LIs bet
ween the LI methods for the normal group, In contrast, total PCNA LIs
were found to be significantly different in the resected cancer patien
ts when compared to either BrdUrd (P = 0.005) or [H-3]thymidine (P < 0
.001). A significant difference (P = 0.010) in total PCNA LI but not i
n total [H-3]thymidine or BrdUrd LIs was also observed between normal
controls and resected colorectal cancer subjects, Compartmental analys
is of the cancer group versus the normals showed a significant differe
nce in compartments 1 and 3 for PCNA LIs only, The reproducibility of
two PCNA LI counts was excellent (r = 0.9), In addition, the reliabili
ty of mean LIs were >0.8 with the exception of [3H]thymidine in the no
rmal group (0.7). These study results demonstrate that PCNA LIs in hum
an rectal mucosal biopsies are correlated highly with other more commo
nly used cellular proliferation measurements; however, PCNA LIs were f
ound to be significantly higher than the other two methods in the rese
cted colorectal cancer subjects.